1. Fayter D, Wijnen B, Ramaekers BLT, Otten T, Witlox W, Ryder S, et al. Fenfluramine for treating Dravet syndrome: a Single Technology Assessment. York: Kleijnen Systematic Reviews Ltd.; 2020.
2. National Institute for Health and Care Excellence. Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]. Final appraisal determination committe papers [Internet]. London: National Institute for Health and Clinical Excellence, 2022. 171p. https://www.nice.org.uk/guidance/ta808/evidence/final-appraisal-determination-committee-papers-pdf-11134456957. Accessed 1 Sep 2022.
3. National Institute for Health and Care Excellence. Fenfluramine for treating seizures associated with Dravet syndrome: Technology appraisal guidance [TA808] [Internet]. London: NICE, 2022. https://www.nice.org.uk/guidance/ta808. Accessed 19 Sep 2022.
4. National Institute for Health and Care Excellence. Fenfluramine for treating Dravet syndrome [ID1109]. Final scope [Internet]. London: National Institute for Health and Clinical Excellence, 2020. 4p. https://www.nice.org.uk/guidance/gid-ta10373/documents/final-scope-2. Accessed 11 Aug 2020.
5. Zogenix International Ltd. Fenfluramine for treating Dravet syndrome [ID1109]: Submission to National Institute of Health and Care Excellence. Single technology appraisal (STA): Document B - Company evidence submission: Zogenix International Ltd., 2020. 182p.